Presentation is loading. Please wait.

Presentation is loading. Please wait.

Advances in Molecular Biology of Lung Disease

Published byShauna Dennis Modified over 6 years ago

Similar presentations

Presentation on theme: "Advances in Molecular Biology of Lung Disease"— Presentation transcript:

1 Advances in Molecular Biology of Lung Disease
Claire Rooney, MBChB, Tariq Sethi, MD, PhD  CHEST  Volume 148, Issue 4, Pages (October 2015) DOI: /chest Copyright © 2015 The American College of Chest Physicians Terms and Conditions

2 Figure 1 Target oncogenes in adenocarcinoma.3–10 ALK = anaplastic lymphoma kinase; BRAF = protein kinase B-raf; EGFR = epidermal growth factor receptor; FGFR = fibroblast growth factor receptor; KRAS = Kirsten rat sarcoma viral oncogene homolog; MET = hepatocyte growth factor receptor; PI3KCA = phosphoinositide-3 kinase catalytic alpha polypeptide; PTEN = phosphatase and tensin homolog; RET = “rearranged during transfection” protooncogene. CHEST  , DOI: ( /chest ) Copyright © 2015 The American College of Chest Physicians Terms and Conditions

3 Figure 2 Target oncogenes in squamous cell carcinoma.8,11,12 DDR2 = discoidin domain receptor tyrosine kinase 2. See Figure 1 legend for expansion of other abbreviations. CHEST  , DOI: ( /chest ) Copyright © 2015 The American College of Chest Physicians Terms and Conditions

4 Figure 3 A, Downstream EGFR signaling. B, Location and effect of most common EGFR mutations. AKT = protein kinase B; ATP = adenosine triphosphate; ERK = extracellular signal-regulated kinase; MEK = dual specificity mitogen-activated protein kinase; PI3K = phosphoinositide-3 kinase; PIP3 = phosphatidylinositol 3,4,5 trisphosphate; TKI = tyrosine kinase inhibitor. See Figure 1 legend for expansion of other abbreviations. (Illustrations by Haderer & Muller Biomedical Art, LLC.) CHEST  , DOI: ( /chest ) Copyright © 2015 The American College of Chest Physicians Terms and Conditions

5 Figure 4 ALK mutations and downstream signaling. JAK = Janus kinase; mTOR = mammalian target of rapamycin; STAT = signal transducer and activator of transcription. See Figure 1 and 3 legends for expansion of other abbreviations. (Illustrations by Haderer & Muller Biomedical Art, LLC.) CHEST  , DOI: ( /chest ) Copyright © 2015 The American College of Chest Physicians Terms and Conditions

Download ppt "Advances in Molecular Biology of Lung Disease"

Similar presentations

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Lung Cancer Tumour Markers

Lung Cancer Tumour Markers
Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 
The JAK-STAT signaling system represents a series of reactions that take place when a hormone binds a receptor that uses this system. While the hormone.

The JAK-STAT signaling system represents a series of reactions that take place when a hormone binds a receptor that uses this system. While the hormone.
Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.
Air Pollution and Chest Disease

Air Pollution and Chest Disease
Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance  David S. Siegel  Seminars in Hematology 

Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance  David S. Siegel  Seminars in Hematology 
by Rogelio Zamilpa, and Merry L. Lindsey

by Rogelio Zamilpa, and Merry L. Lindsey
Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis

Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis
LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT  Jacob M. Kaufman,

LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT  Jacob M. Kaufman,
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R 
Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era  Joon H. Uhm, MD, Alyx B. Porter,

Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era  Joon H. Uhm, MD, Alyx B. Porter,
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values  Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values  Geun Dong Lee, MD, PhD, Seung Eun Lee, MD,
Molecular pathology of non-small cell lung cancer

Molecular pathology of non-small cell lung cancer
Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E

Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E
Ground glass opacities: Imaging, pathology, and gene mutations

Ground glass opacities: Imaging, pathology, and gene mutations
Figure 3 Defects in the T cell receptor signalling pathway

Figure 3 Defects in the T cell receptor signalling pathway
Volume 150, Issue 3, Pages (September 2018)

Volume 150, Issue 3, Pages (September 2018)
Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas?  Nicolas Girard, MD  Journal of Thoracic.

Similar presentations

Ads by Google